Compare Adaptive Biotechnologies Corp (ADPT) vs Marathon Petroleum Corp (MPC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Marathon Petroleum Corp — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Marathon Petroleum Corp trades at $280.72 (market cap $77.75B). The key difference: Marathon Petroleum Corp is far larger — about 23.3× Adaptive Biotechnologies Corp's market cap, and Marathon Petroleum Corp pays a 1.47% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | MPC | |
|---|---|---|
Market Cap | $3.33B | $77.75B |
Sector | Health | Energy |
52-Week High | $22.37 | $268.99 |
52-Week Low | $10.24 | $158.59 |
Enterprise Value | $3.19B | $109.93B |
Dividend Yield | — | 1.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Marathon Petroleum (MPC) trades at $266.33, showing minimal daily movement (-0.01%) but maintaining strong momentum with a 52% gain over the past six months. The stock demonstrates robust profitability with ROE of 27.92% and net income margin of 3.42%, supported by favorable refining margins from global supply disruptions. Recent earnings show mixed performance with Q3 2025 missing estimates but Q1 2026 beating expectations by 123%.
MPC presents a compelling investment case with attractive valuation (P/E 17.71, P/S 0.6) and strong analyst support (76% buy ratings). However, declining revenue trends from $177.5B in 2022 to $132.7B in 2025 and rising debt-to-asset ratio to 42.59% warrant caution. The upcoming Q2 2026 earnings on August 4th will be critical for validating the current bullish sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →
